These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 27430478)

  • 21. Limited prognostic value of preoperative circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer.
    Meyer CP; Pantel K; Tennstedt P; Stroelin P; Schlomm T; Heinzer H; Riethdorf S; Steuber T
    Urol Oncol; 2016 May; 34(5):235.e11-6. PubMed ID: 26795608
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Using circulating tumor cells to inform on prostate cancer biology and clinical utility.
    Li J; Gregory SG; Garcia-Blanco MA; Armstrong AJ
    Crit Rev Clin Lab Sci; 2015; 52(4):191-210. PubMed ID: 26079252
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer.
    Gonzales JC; Fink LM; Goodman OB; Symanowski JT; Vogelzang NJ; Ward DC
    Clin Genitourin Cancer; 2011 Sep; 9(1):39-45. PubMed ID: 21723797
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate cancer androgen receptor splice variant 7 biomarker study - a multicentre randomised feasibility trial of biomarker-guided personalised treatment in patients with advanced prostate cancer (the VARIANT trial) study protocol.
    Clark E; Morton M; Sharma S; Fisher H; Howel D; Walker J; Wood R; Hancock H; Maier R; Marshall J; Bahl A; Crabb S; Jain S; Pedley I; Jones R; Staffurth J; Heer R
    BMJ Open; 2019 Dec; 9(12):e034708. PubMed ID: 31857319
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Liquid biopsy and PCR-free ultrasensitive detection systems in oncology (Review).
    Finotti A; Allegretti M; Gasparello J; Giacomini P; Spandidos DA; Spoto G; Gambari R
    Int J Oncol; 2018 Oct; 53(4):1395-1434. PubMed ID: 30085333
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer.
    Bitting RL; Healy P; Halabi S; George DJ; Goodin M; Armstrong AJ
    Urol Oncol; 2015 Mar; 33(3):110.e1-9. PubMed ID: 25595577
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment-induced changes in the androgen receptor axis: Liquid biopsies as diagnostic/prognostic tools for prostate cancer.
    Prekovic S; Van den Broeck T; Moris L; Smeets E; Claessens F; Joniau S; Helsen C; Attard G
    Mol Cell Endocrinol; 2018 Feb; 462(Pt A):56-63. PubMed ID: 28882555
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancer.
    Xia S; Kohli M; Du M; Dittmar RL; Lee A; Nandy D; Yuan T; Guo Y; Wang Y; Tschannen MR; Worthey E; Jacob H; See W; Kilari D; Wang X; Hovey RL; Huang CC; Wang L
    Oncotarget; 2015 Jun; 6(18):16411-21. PubMed ID: 25915538
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circulating tumor cells in prostate cancer: beyond enumeration.
    Chen JF; Lu YT; Cheng S; Tseng HR; Figlin RA; Posadas EM
    Clin Adv Hematol Oncol; 2017 Jan; 15(1):63-73. PubMed ID: 28212371
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integration of Liquid Biopsies in Clinical Management of Metastatic Prostate Cancer.
    Tulpule V; Morrison GJ; Falcone M; Quinn DI; Goldkorn A
    Curr Oncol Rep; 2022 Oct; 24(10):1287-1298. PubMed ID: 35575959
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circulating tumor cells and their role in prostate cancer.
    Maas M; Hegemann M; Rausch S; Bedke J; Stenzl A; Todenhöfer T
    Asian J Androl; 2017 Aug; 21(1):24-31. PubMed ID: 28836508
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circulating tumour cells as biomarkers of prostate, bladder, and kidney cancer.
    Gorin MA; Verdone JE; van der Toom E; Bivalacqua TJ; Allaf ME; Pienta KJ
    Nat Rev Urol; 2017 Feb; 14(2):90-97. PubMed ID: 27872478
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pancreatic cancer: Are "liquid biopsies" ready for prime-time?
    Lewis AR; Valle JW; McNamara MG
    World J Gastroenterol; 2016 Aug; 22(32):7175-85. PubMed ID: 27621566
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Circulating tumor cells in localized prostate cancer: isolation, cultivation in vitro and relationship to T-stage and Gleason score.
    Kolostova K; Broul M; Schraml J; Cegan M; Matkowski R; Fiutowski M; Bobek V
    Anticancer Res; 2014 Jul; 34(7):3641-6. PubMed ID: 24982381
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SiNVICT: ultra-sensitive detection of single nucleotide variants and indels in circulating tumour DNA.
    Kockan C; Hach F; Sarrafi I; Bell RH; McConeghy B; Beja K; Haegert A; Wyatt AW; Volik SV; Chi KN; Collins CC; Sahinalp SC
    Bioinformatics; 2017 Jan; 33(1):26-34. PubMed ID: 27531099
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular characterization and clinical utility of circulating tumor cells in the treatment of prostate cancer.
    Lorente D; Mateo J; de Bono JS
    Am Soc Clin Oncol Educ Book; 2014; ():e197-203. PubMed ID: 24857103
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of BRAF-V600E and V600K in melanoma circulating tumour cells by droplet digital PCR.
    Reid AL; Freeman JB; Millward M; Ziman M; Gray ES
    Clin Biochem; 2015 Oct; 48(15):999-1002. PubMed ID: 25523300
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Classifying circulating tumor cells to monitor cancer progression.
    Economopoulou P; Georgoulias V; Kotsakis A
    Expert Rev Mol Diagn; 2017 Feb; 17(2):153-165. PubMed ID: 28032524
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Circulating tumor DNA in advanced prostate cancer: transitioning from discovery to a clinically implemented test.
    González-Billalabeitia E; Conteduca V; Wetterskog D; Jayaram A; Attard G
    Prostate Cancer Prostatic Dis; 2019 May; 22(2):195-205. PubMed ID: 30413805
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patients.
    Thalgott M; Rack B; Eiber M; Souvatzoglou M; Heck MM; Kronester C; Andergassen U; Kehl V; Krause BJ; Gschwend JE; Retz M; Nawroth R
    BMC Cancer; 2015 Jun; 15():458. PubMed ID: 26051431
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.